Welcome to the website of the European Society of Pharmacogenomics and Personalised Therapy (ESPT)!
ESPT is the primary professional scientific non-profit society for pharmacogenetics and pharmacogenomics in Europe, founded in 2011. ESPT aims at enabling the integration of pharmacogenomics and pharmacogenetic information into today’s health care. Most important activities are the organized yearly scientific meetings (Seville 2019, Catania 2017, Budapest 2015, Lisbon 2013, Bled 2011) and summer schools (Kiel 2020, Geneva 2018, Belgrade 2016, Rome 2014, Ljubljana 2012) to facilitate ESPT mission and vision .
The Society has an Executive Board representing pharmacogenomic professionals. The Society consists of four Divisions : Clinical Implementation, Research, Education and Communications. In addition, the Society is proud to have its own journal: Drug Metabolism and Personalized Therapy, DMPT. The society reaches over 600 member, consisting of individual members, Research Groups, National Pharmacogenomics/genetics Societies, Corporate members and a Scientific Advisory Board . Benefits of joining the Society are that members get access to DMPT, to ESPT members-only page and get great opportunity to join ESPT Conferences and Summer Schools.
One of the important goals of our society is to bring together all relevant stakeholders to exchange the latest information on pharmacogenomics and pharmacogenetics, to stimulate new research and collaborations in this field and to facilitate implementation of pharmacogenomics/pharmacogenetics into clinical practice.
Do you want to be a part of this exciting Society, and contribute to the ESPT Mission and Vision? Then do not wait any longer, and join ESPT ! We are looking forward to have you on board as an ESPT member and meet you soon at one of our activities!
OUR MISSION IS TO CONTRIBUTE TO SAFER AND MORE EFFICENT USE OF DRUG THERAPY FOR EVERY PATIENT IN EUROPE, UTILIZING THE POTENTIAL OF PHARMACOGENOMIC* INFORMATION.
Aims of ESPT
ESPT aims to stimulate the translation of pharmacogenetics/genomics research into clinical use, by:
- Supporting clinical implementation both on a national and clinical laboratory level
- Stimulating exchange of information between stakeholders
- Facilitating research
- Providing and structuring education
- Serving as a partner for industry
Giving input to regulators and policy makers in the field of personalised medicine*
Pharmacogenomics corresponds to theapplication of the systematic screening of the human genome for the search of genetic markers sensitive to the action of the drugs either at the level of the cellular or molecular targets,at the level of the drug metabolismor even at the level of the pathological pathways involved.
* Personalized Medicine
Personalized Medicine refers to a medical model using molecular profiling for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention
ESPT STRATEGIC PLAN
The first, strategic plan is intended to achieve a number of principal objectives, with the priorities and tactical implementation being guided by the ESPT Membership.
These internal and external changes are all intended to maintain ESPT as a valid and credible resource of expertise for the improvement of patient care through laboratory medicine.
To improve and maintain the multidisciplinary and international leadership of ESPT in specific Pharmacogenomics (PGX) biomarkers activities. PGX is the best example of personalized therapy and personalized medicine.
To ensure that its standardization and research activities are more oriented towards the patient and towards promoting the health and well-being of the individual.
To ensure consistency between its activities and the stated expectations of the ESPT members, recognizing the needs of both developed and developing countries. To increase the number of National Societies and Networks.
To develop and maintain ESPT communications, to promote publications and products from ESPT, including recommendations, guidelines, consensus reports, commentaries, and to set up joint promotion activities with other European and international organizations.
To establish collaborations, joint meetings and projects with European and international organizations having interest in the field of PGX and – personalized medicine.
To promote ESPT through international and regional congresses.
To promote Members’ activities.
To encourage scientific and professional development of individuals in Research groups and the recruitment of new members and experts to ESPT operating units.
To develop and maintain Public Relations.
Each new ESPT Executive Board revisits and interprets these principal objectives, so that they are fresh and relevant to current issues, challenges and opportunities.
The result is a series of specific strategic objectives for the period of an Executive board.
EXECUTIVE BOARD MEMBERS
Vangelis G. Manolopoulos
To be elected
To be elected
Corporate Members Representative
PROF. GÉRARD SIEST (2012–2016)
Siest Prof. Gérard Siest was among the founding members of ESPT in 2011, and was an important inspiratory and driver of the society. He served as ESPT president from 2012–2016. Under his leadership, ESPT gained worldwide visibility and became an important scientific stakeholder in the field of pharmacogenomics and personalised medicine.
Prof. Siest was emeritus professor of molecular biology and biochemical pharmacology at the Faculty of Pharmaceutical Sciences and former director of the postgraduate course in Biochemical Pharmacology at the University Henri Poincaré in Nancy, France.
He was also the founder and head of the clinical laboratory and research group of the “Centre de Médecine Preventive” in Nancy for 37 years (1968-2005). As an extremely hardworking person Prof. Gérard Siest was well known to the scientific community as author of more than 800 publications in peer reviewed journals and his work was honoured by 27 awards from sixteen different countries.
He was strongly involved in activities of many international and european professional societies, and served as President of IFCC (1991-1996). Prof Siest also was active in many editorial boards, and had an important role in the ESPT journal DMPT.
Prof. Dr. Ron H.N van Schaik (2016-2020)
Prof Dr Ron HN van Schaik was among the founding members of ESPT in 2011, and succeeded Prof Gerard Siest. Prof van Schaik is the second ESPT President, serving from 2016–2020. Under his leadership, ESPT maintained worldwide visibility in the field of pharmacogenomics and personalised medicine. Under his presidency, the 2017 Catania and 2019 Seville ESPT Congresses were organized, as well as the 2018 ESPT Summerschool in Geneva and he achieved 5 National PGx Societies to join ESPT.
Prof. Dr. Ron H.N. van Schaik studied Chemistry at Utrecht University, receiving his PhD in 1992. After a 4 year post-doc at the Dept. Endocrinology, Erasmus MC Rotterdam and a 1 year post-doc at the Daniel den Hoed Cancer Center, he joined the Dept. Clinical Chemistry at Erasmus MC, receiving his Dutch and European registration (EuSpML) in April 2003. Prof van Schaik continued to work at the Dept Clinical Chemistry, becoming an Associate Professor in 2008 and a Full Professor Pharmacogenetics in 2013. He is now Director of the IFCC Expertcenter for Pharmacogenetics. Prof van Schaik is active in National and International committees on Pharmacogenetics (IFCC Task Force PGx (chair), IFCC cfDNA Working group (chair), AACC Personalised Medicine Division (founding member), AMP Expertgroup PGx, PGRN (founding member), IATDMCT PGx Committee (chair), IUPHAR PGx Committee, NVKC Molecular Biological Diagnostics (chair)), KNMP/Dutch PGx Working Group and the EMA PGx Working group.
H-factor: 72 (Google Scholar 2020)
PAST AND PRESENT BOARD MEMBERS AND TERMS OF OFFICE
|MEMBER||COUNTRY||1st TERM||2nd TERM||EXTENSION||REMARKS||ROLE|
|1||Gerard Siest||FRA||2012-2016||–||–||Founding Member||President (2012-2016)||–|
|2||Ron van Schaik||NED||2012-2016||2016-2020||2020-2022||Founding Member||President (2016-2020)||Past-president (2020-2022)|
|3||Vangelis Manolopoulos||GRE||2012-2016||2016-2020||2020-2022||Founding Member||President-elect (2016-2020)||President (2020-2022)|
|4||Janja Marc||SLO||2012-2016||2016-2020||Founding Member||Secretary (2012-2016)||–|
|5||Adriano Henney||UK||2012-2014||–||–||Founding Member||Treasurer (2012-2014)||–|
|6||Sofia Siest||FRA||2012-2016||2016-2020||–||Founding Member||Treasurer (2014-2016)||–|
|7||George Patrinos||GRE||2012-2014||–||–||Founding Member||–||–|
|8||Adrian Llerena||SPA||2012-2016||2018-2022||–||Founding Member||–||–|
|9||Maurizio Simmaco||IT||2013-2017||2017-2021||–||–||Treasurer (2018-2022)||–|
|10||Ingolf Cascorbi||GER||2013-2017||2017-2021||Treasurer (2016-2018)|
SCIENTIFIC ADVISORY BOARD
Peter Mayer Abt
Anne K. Daly
Mary V. Relling
Magnus Ingelman Sundberg
Giulio Superti Furga
(Scientific Research Division)
(Scientific Research Division)
Pharmacogenomics of Prostate Cancer
(Scientific Research Division)
(Scientific Research Division)
Circulating free DNA
(Scientific Research Division)
Ron van Schaik
Harmonization of PGx testing and PGx guidelines
(Clinical Implementation Division)
Ron van Schaik
Ron van Schaik
Joint working group Molecular Biology with EFLM
Ron van Schaik
The official journal of ESPT is Drug Metabolism and Personalized Therapy (DMPT).
Drug Metabolism and Personalized Therapy provides up-to-date Research Articles, Reviews and Opinion Papers in the wide field of drug metabolism research, covering established, new and potential drugs, environmentally toxic chemicals, the mechanisms by which drugs may interact with each other and with biological systems, and the pharmacological and toxicological consequences of these interactions and drug metabolism and excretion. Areas covered include: drug metabolizing enzymes, pharmacogenetics and pharmacogenomics, biochemical pharmacology, molecular pathology, clinical pharmacology, pharmacokinetics and drug interactions, immunopharmacology, and neuropsychopharmacology. DMPT also publishes Short Communications, Letters to the Editor, Case Reports, and Editorials.
We would like to invite all members of ESPT to submit their scientific work – Reviews, Research Articles, Short Communications, Case Reports, Letters to the Editor – to DMPT.
Publication of color figures is free of charge both in online and print editions.
• Ahead of print online publication for all accepted papers after peer reviewing.
• Rapid publication times: max. 3 weeks from acceptance to online publication.
• High quality manuscript processing through Thomson Reuters ScholarOne.
• Open Access option available for all accepted papers.
Please submit at: https://mc.manuscriptcentral.com/dmpt.
Chemical Abstracts, Elsevier EMBASE, Elsevier BIOBASE, ISI BIOSIS Previews, ISI International Pharmaceutical Abstracts, Pro Quest Natural Sciences – Toxline, and Medline.
Kalman LV, Agúndez JA, Appell ML, Black JL, Bell GC, Boukouvala S, Bruckner C, Bruford E, Bruckner C, Caudle K, Coulthard S, Daly AK, Del Tredici AL, den Dunnen JT, Drozda K, Everts R, Flockhart D, Freimuth R, Gaedigk A, Hachad H, Hartshorne T, Ingelman-Sundberg M, Klein TE, Lauschke VM, Maglott DR, McLeod HL, McMillin GA, Meyer UA, Müller DJ, Nickerson DA, Oetting WS, Pacanowski M, Pratt VM, Relling MV, Roberts A, Rubinstein WS, Sangkuhl K, Schwab M, Scott SA, Sim SC, Thirumaran RK, Toji LH, Tyndale R, van Schaik RH, Whirl-Carrillo M, Yeo KJ, Zanger UM.
Clin Pharmacol Ther. 2015 Oct 19. doi: 10.1002/cpt.280.
“Pharmacogenomics Education: International Society of Pharmacogenomics Recommendations for Medical, Pharmaceutical, and Health Schools Deans of Education” Gurwitz D. and Al. The Pharmacogenomics Journal (2005) 5, 221-225
Santorini Conference on Prospective Biology – Round Table Report, Pharmacogenomics, 2011, 12 (5), 597-610 (Santorini, 30th September – 2nd October 2010)
An update from The European Society of Pharmacogenomics and Theranostics. Pharmacogenomics (2012) 13(2):133-135
Recommendation of the European Society of Pharmacogenomics and Theranostics, Albertini L. and Al. Drug Metab. Drug Interact (2012) 27(2):119
Pharmacogenomics and Theranostics in practice – A summary of the Euromedlab-ESPT (The European Society of Pharmacogenomics and Theranostics) satellite symposium, May 2013. EjIFCC 2013 Vol;24, n. 3-4
Implementation of a companion diagnostic in the clinical laboratory: The BRAF example in melanoma; Clin Chim Acta. 2015 Jan 15;439:128-36.
Clinical Application Of Pharmacogenetics: Where Are We Now? EjIFCC 2013 Vol;24, n. 3-4
Second International ESPT Meeting – Lisbon, Portugal, 26–28 September 2013: Pharmacogenomics: from cell to clinic (Part 1 and 2). Pharmacogenomics (2014) 15(5), 593–599; Pharmacogenomics (2014) 15(6), 739–744
Conference Scene: Systems medicine, personalized health and therapy. Pharmacogenomics (2015) 16(14):1527-39
Article 1. – Name
The society, established under the French law dated 1st July 1901 and the decree dated 16th August 1901, is called:
“Société Européenne de Pharmacogénomique et Thérapie personnalisée – European Society of Pharmacogenomics and Personalised Therapy” (ESPT).
Article 2. – Objective
The European Society of Pharmacogenomics and Personalised Therapy is a non-profit making organisation. Its objective is to promote training and research in pharmacogenomics and personalised therapy, in order to produce quality-controlled information for applications in clinical practice and for patients. It aims to facilitate contact between all those sharing its objectives, in particular those working in Europe. The Society will encourage and endeavour to integrate fundamental multidisciplinary approaches to research and transform them into clinical benefits, both for professional training and education of the general public, in all the areas of human pharmacogenomics, clinical pharmacology, laboratory medicine and personalised medicine.
Article 3. – Life-span
The Society has been founded with an unlimited life-span.
Article 4. – Registered address
The registered address of the Society is 30 rue Lionnois – Présidence de l’Université de Lorraine – UMR INSERM U1122 ; IGE-PCV– 54000 NANCY – FRANCE
The Executive Office and corresponding address is located at Via Carlo Farini, 81, 20159, MILAN, ITALY.
Article 5. – Members of the Society
There are 7 categories of members.
5.1. Individual (full member)
Membership will be open to any person working in the pharmacogenomic and personalised medicine field, preferably, but not exclusively, based in a European country.
5.2. Student (full member)
Students, including PhD students are included in this category (under 35 years old).
5.3. National organisations (associate members)
The members of National societies or corresponding networks related to pharmacogenomics that have firmly agreed to collaborate with ESPT in the name of their society. A national representative full member is in charge of the society members.
5.4. Scientific group (associate members)
It is a category of individual members in the scientific groups. A Scientific Group ESPT full member is in charge of the research group members.
5.5. Corporate member (full member)
Any company involved in the field of pharmaceutics, biotechnology, laboratory medicine or related disciplines may become a corporate member.
5.6. Scientific Advisory Board member (full member)
Experts in the field of pharmacogenomics and personalised therapy proposed by any ESPT member and accepted by the General Assembly. They are nominated for a period of 4 years renewable.
5.7. Honorary member (full member)
This distinction is awarded to those who have made an exceptional contribution to the field of pharmacogenomics and personalised therapy.
Collaboration with European and International Institutions
ESPT will sign agreement with European and International Institutions, foundations, research institutes and organisations working in the field for avoiding overlapping activities.
Article 6. – Subscriptions
Individual full members, students, corporate members, associate and national society members will pay an annual subscription, the amount of which will be determined by the Executive Board. The subscription for students may be set at a lower amount than that of other members.
Subscriptions will be waived for honorary and scientific advisory board members.
Subscriptions are given in euros, payable at the beginning of each civil year for each paying membership category.
Article 7. – General provisions
To join the Society, an applicant must be approved by the Executive Board which will be confirmed by a majority vote at each of its meetings on the applications for admission presented.
7.2. Loss of membership statutes
Membership of the Society may end:
- by voluntary resignation;
- by death;
- by the dissolution, closure or merger of an organisation which is a member;
- by in arrear of payment annual subscription for two consecutive years. The exclusions must be decided by the Executive Board by a majority vote after getting a statement of the member concerned. The member concerned may not take part in this vote and may not vote by procuration.
Article 8. – Activities
The Society organises, co-organises and supports meetings, symposia, conferences and other scientific meetings as well as educational programmes in order to produce information for applications in clinical practice and for patients in the field of pharmacogenomics and personalised therapy. A major event is the Society’s annual congress, which should preferably take place in the spring or autumn. A General Assembly will take place during this event. Other activities contributing to the Society’s objectives may also be undertaken, such as participation in grant applications, in clinical trials, multi-site trials, evaluation of biomarkers, drawing up and preparing critical independent expert opinions recommendations appropriate to the Society’s areas of interest.
Article 9. – Publications
The Society will aim to publish the programs of its congresses and abstracts of the presentations. From time to time, the Society will also publish its committees’ reports, and directives and recommendations after ratification by the Executive Board. At present, the journal “Drug Metabolism and Personalised Therapy” (DMPT), published by De Gruyter, is the Society’s official journal. The members of the Executive Board will work closely with the chief editor of DMDI and will encourage members of the Society to submit their work to the journal. The Society reserves the right to periodically examine and modify its publication strategies.
Article 10. – The General Assembly
All members in good standing may take part in the General Assembly. General Assembly may be Ordinary or Extraordinary. Meetings considered as extraordinary will be those where decisions are to be taken concerning modification of the statutes and winding up the Society.
A General Assembly will take place at least once a year and whenever necessary. The date and place of the General Assembly will be communicated one year prior. Notices to members convening a meeting must show the agenda and should to be sent (either by letter or electronic mail) to all members at least 15 days before the meeting. Minutes of a General Assembly will be taken to record decisions taken and acceptance of the budget. They will constitute an official document of the Society.
No quorum is required for Ordinary General Assembly. Decisions taken in an Extraordinary General Assembly will be valid if 30% of members in good standing are present or represented. If this quorum is not reached, the Extraordinary General Assembly will be reconvened and will constitute a quorum independent of the number of delegates.
Each member in good standing has one vote. A member may give written procuration to vote to another member. One member may not represent more than one other member. If the number of votes is equal, the President, or in case of absence, the president elect, will have the casting vote.
Ordinary decisions are taken by a simple majority of votes. Decisions in an Extraordinary General Assembly are taken with a two-thirds majority of the members present or represented.
The General Assembly will approve the budget and the accounts of the Society, elect or dismiss members of the Executive Board and may modify the articles of association and dissolve the Society. The agenda of the General Assembly must include:
- presentation, by the President or Secretary, of the Society’s activities over the past year
- presentation by the Secretary or Treasurer of the Society’s finances validated by independent company.
- discussions and decisions concerning the above
- creation of divisions and the reports of their activities
- presentation of plans and objectives of divisions for the next elective period
- determination of members’ annual subscriptions
- approval of the choice of location for future General Assembly
- any other questions proposed by the Executive Board, particularly broad general policies.
Article 11. – The Executive Board
11.1. The Executive Board is the governing body of the Society and has all the powers necessary to take decisions. It assumes responsibility for all questions except those specifically reserved by law and by these Articles of Association to the General Assembly, to which it is responsible. The minutes of Executive Board meetings will be recorded to provide a record of activities envisaged and decisions taken. They will constitute official documents of the Society.
The Executive Board will be composed of:
- The President
- The President elect
- The Immediate Past-President
- The Treasurer
- The Secretary General
- Usually three to six Councillors, among which a Corporate Representative, to be nominated by the Corporate members
The executive members should represent various areas of expertise and a broad geographical location. It will aim to maintain male/female equilibrium. The term of office of a member of the Executive board will be four years. Members of the Executive Board are re-eligible once at the end of their term of office.
Any member of the Executive Board who has been repeatedly inactive in the Society’s affairs, being absent on any executive board meeting within a year and/or developing activities in conflict with ESPT, as judged by the Executive Board, may be dismissed by a simple majority decision of the General Assembly.
The Executive Board will confirm the selection of the General Secretary, the Treasurer and give specific task to the members at large. The members of the Executive Board are appointed for a period of 4years which can be renewed by re-election at the General Assembly only once, limiting board membership to 8 consecutive years. This period finishes at the end of the General Assembly ruling on the accounts of the previous accounting period concurrent with the final year of their term of office as administrator. If an executive board member is elected as president-elect, he/she will remain on the Executive Board for the full sequence of the two year term as president-elect, two year as president and two year as past-president (in total 6 years), irrespective of the 8 year term specified above, to ensure continuity in the board.
The corporate representative will be nominated by the corporate members, and needs acceptance of the Executive Board.
11.3. Elections and appointments
If a vacancy occurs, the Board can temporarily replace a member or members. Definitive replacement occurs at the next General Assembly. The power of the substitute Board member ends when the term of office of the member replaced would normally have terminated.
If members of the Board, and in particular the President, reach the end of their terms of office without new elections in view immediately, they will remain in office until the next election in order to ensure that the Society always has a body with the power to represent it, manage its affairs and act in its name.
At each General Assembly, new members of the Executive Board may be proposed and elected to maintain a minimum of 7 members. In accordance with article 5, any member of the Society working in the field of pharmacogenomics and personalised medicine is eligible.
For maintaining equilibrium between the different disciplines, and a balance between previous members and new members, a nomination committee will be created one year before the elections.
11.4. Board meetings
The Executive Board will meet regularly, at least annually and at any other time if the President requests it. The Executive Board will also meet on written request from 5 of its members. The agenda of the Executive Board must be sent with the notification (as a simple letter or e-mail) to the members of the Executive Board at least 10 days before the meeting with the necessary documents. Each member of the Executive Board has one vote. If there is an equal number of votes, the President or, in case of absence, the President elect, will have the casting vote. A simple majority is required for decisions.
11.5. Steering committee
This is composed of the President, President-elect, the Past President, the General Secretary and the Treasurer. It is authorised to act in the name of the Executive Board between the meetings of the latter. It follows the Society’s affairs and meets at least twice a year.
Article 12. Responsibilities
The President chairs the Executive Board, the Steering Committee and the Society. The President is responsible for carrying out the decisions of the Executive Board and ensuring that the Society functions well.
The President represents the Society in all public affairs. In particular, the President is entitled to act in legal proceedings to defend the name of the Society and as plaintive with the authorisation of the Executive Board. Under the same conditions the President may formulate an appeal.
The President may only come to a compromise with the authorisation of the Executive Board.
The President convenes the General Assembly and the Executive Board as well as the Steering Committee and chairs all the meetings. The President fixes and chairs Executive Board meetings, Steering Committee and the General Assembly. At the President’s request, the organisation of these meetings may be initiated or organised by the General Secretary. In the absence of the President, the President elect acts as a substitute. In exceptional circumstances, the Executive Board may select another member of the executive to assume the President’s responsibilities until elections can be organised.
Neither the President nor any other person appointed by of being member of the Executive Board may, without the prior agreement of the Executive Board, agree to any operation whatsoever, and particularly any financial transaction involving more than 12,000 euros.
The President may delegate in writing some of the powers set out above to another member, an official of the Society or any person that could be considered appropriate.
12.2 President elect
The President-elect shall:
- represents the society in the case of short-term hindrance of the president
- is member of the steering committee
- may assist the president in all tasks
- automatically becomes president after one election-period (4 years)
12.3 General Secretary
The General Secretary shall:
- maintain an actual member directory of the Society including the voting members
- keep the records of all meetings of the General Assembly, the Executive Committee and other boards
- distribute the agenda for the meetings of the General Assembly at least 15 days prior to the meeting, and shall distribute the minutes of the meetings not later than three months after the meeting
- collect and distribute information with reference to the activities and objectives of the Society from and to member societies and associations as well as members
The task of the treasurer is to render annually a complete financial account and submit a proposed budget to the General Assembly Financial experts could bring advice and organize a finance committee.
Article 13. – Divisions
The General Assembly and the Executive Board may create ad hoc divisions and working groups. The members of these divisions, working groups are appointed for a period of 4 years, which can be renewed once.
The Executive Board appoints the chairs of each division for 4 years. These divisions will regularly prepare reports for the Executive Board and cannot represent the Society without written consent. The composition of the divisions and their objectives will be presented to the General Assembly and must be approved. The division chairs could be invited members to the Executive Board. The divisions and permanent committees are currently as follows:
13.1. Education and Training division
This division is composed of full members and associate members. They coordinate all ESPT training activities and create the necessary working groups.
13.2. Scientific division
This division is composed of full members and associate members. They coordinate all ESPT Scientific division activities and create the necessary working groups.
13.3. Clinical Implementation division
This division is composed of full members and associate members. They coordinate all ESPT Clinical Implementation division activities and create the necessary working groups.
13.4. Communication division
This division is composed of full members and associate members. They coordinate all ESPT public relations and cooperation activities and create the necessary working groups.
- Other divisions or committees could be created and validated at the next General Assembly. Divisions can be divided in active subunits.
Article 14. – Committees
Short term committees (two years) could be created for preparing useful recommendations, opinions papers or consensus reports. Those committees could be scientific or educational. Joint committees with other institutions are the best strategy. They are usually composed by a Chairman nominated by the Executive Board and 2 members.
Article 15. – Organisation of the General Assembly (G.A.)
The Executive Board will decide where future meetings will take place in conjunction with the Congress and Meetings division. The sites suggested must be accepted by the General Assembly. Except when otherwise stated in its Articles of Association, all the elections or decisions, at the Ordinary General Assembly or in the Executive Board may be taken by a simple majority vote.
The sites chosen for the ESPT congresses and the G.A. must be decided at least 1 year in advance. The Executive Board must seek invitations for the desired locations and select a site. A contract should be signed between ESPT and the organizer of the ESPT congress.
Article 16. – Vote and elections of the Executive Board
1/ A Nomination Committee (NC) is created one years before the renewal of the Board members. The Nomination Committee is composed of a minimum of 4 members including the Past president, the President-elect and the previous NC chairman. The Chairman of the Nomination Committee is designated by the Executive Board. The Nomination Committee propose candidates for the election of the President, the President-elect and eventually for the General Secretary and the Treasurer and the members of the board at large. The list of candidates should be ready 4 months before the election.
The Executive Board will confirm the selection the General Secretary, the Treasurer and give specific tasks to the members at large. The members of the Executive Board are appointed for a period of 4 years which can be renewed once. This period finishes at the end of the General Assembly ruling on the accounts of the previous accounting period concurrent with the final year of their term of office as administrator.
The election will be organized by the General Secretary and presented at the next General Assembly. The vote could be done electronically one month before. The voting members are the full members in good standing (subcategories 5.1 and 5.2), the leaders of the national societies (5.3), the scientific groups leaders and associate members (5.4), the corporate members (5.5) and the scientific advisory board members (5.6). The results will be presented to the General Assembly for final approval.
2/ A call for candidacy must be made at least six months before the General Assembly.
Article 17. – Winding up the society
Winding up requires a vote with a majority of 2/3 of the members at an Extraordinary General Assembly at which half of the members are present or represented. If the Society is to be dissolved, its assets will be attributed to the International Red Cross or to other charitable associations.